Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.38 |
| ▸ | SCN4A | P35499 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23861677 | 0.89 | SCN9A (0.46) | SCN9AMRGPRX4TRPM8MEN1ALDH1A1 | |
| SCHEMBL18556181 | 0.89 | RAB9A (0.43) | SCN9AMRGPRX4TRPM8MEN1ALDH1A1 | |
| SCHEMBL18571141 | 0.83 | BRD4 (0.41) | SCN9ATRPM8BRD4 | |
| SCHEMBL18556036 | 0.83 | MEN1 (0.46) | SCN9AMRGPRX4MEN1ALDH1A1KMT2A | |
| SCHEMBL30261516 | 0.77 | MRGPRX4 (0.60) | SCN9AMRGPRX4MEN1KMT2ANPC1 | |
| SCHEMBL23861709 | 0.76 | SCN7A (0.45) | SCN9AMRGPRX4TRPM8BRD4SCN5A | |
| SCHEMBL23861668 | 0.75 | SCN7A (0.44) | SCN9AMRGPRX4TRPM8MEN1ALDH1A1 | |
| SCHEMBL21800830 | 0.75 | SCN7A (0.44) | SCN9AMRGPRX4TRPM8MEN1ALDH1A1 | |
| SCHEMBL18556179 | 0.75 | SCN7A (0.44) | SCN9AMRGPRX4TRPM8MEN1ALDH1A1 | |
| SCHEMBL18571134 | 0.75 | SCN7A (0.44) | SCN9AMRGPRX4TRPM8MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200087239-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087239-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C3AR1, LPXN | SCN9A 1789/4885MRGPRX4 39/4885TRPM8 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.